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Background: Predicting response to proton pump inhibitor (PPI) treatment can aid the effective management of
gastroesophageal reflux disease (GERD). The aim was to investigate the predictors of symptomatic response to
pantoprazole in Asian patients with GERD; the first study of its kind in Asian patients.
Methods: Asian patients with GERD symptoms (N = 209) received pantoprazole 40 mg daily for 8 weeks in a
multinational, prospective, open-label study. Response was assessed using ReQuest™. Baseline and demographic
factors were examined using logistic regression to determine if they were related to treatment response.
Results: Response rates were 44.3% (Week 4) and 63.6% (Week 8) in Asian patients versus 60.7% (P < 0.001) and
72.2% (P = 0.010) for the rest of the world. Higher response rates at 8 weeks occurred in patients with erosive
reflux disease (ERD; 71.3%) versus those with non-erosive reflux disease (NERD) at baseline (48.5%). The presence
of ERD (P = 0.0143) and lower ReQuest™-GI scores at baseline (P = 0.0222) were associated with response.
Improvements in quality of life (QoL) and anxiety and depression at 4 and 8 weeks were associated with
treatment response (both P < 0.0001). Patient satisfaction correlated with treatment response (P < 0.0001),
and improvement in anxiety and depression (P < 0.0001) and QoL (P < 0.0001).
Conclusions: Asian patients with GERD, especially those with NERD, may have lower response rates to PPIs than
Western populations. ERD and less severe gastrointestinal symptoms may help to predict symptomatic
responses to PPIs in Asian patients.
Trial Registration: ClinicalTrial.gov identifier: NCT00312806.Background
Despite the potency of proton pump inhibitors (PPIs) on
gastric acid secretion, many patients with gastroesopha-
geal reflux disease (GERD) continue to experience reflux
symptoms while receiving PPI therapy [1-3]. Thus, in
clinical practice, it is important for physicians to under-
stand whether a patient with GERD will respond well or
poorly to the prescribed treatment. To address this ques-
tion, a large worldwide study in GERD patients designed to
approximate ordinary clinical practice was undertaken. The
study aimed to identify patient characteristics predicting* Correspondence: justinwu@cuhk.edu.hk
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reproduction in any medium, provided the orsymptomatic response to pantoprazole treatment (results
for the total population have been previously published [4]).
Although GERD is less common in Asian populations
than in Caucasian populations, the prevalence has
been increasing and it has become an important dis-
ease in the region [5-8]. Endoscopy-based studies tend
to show a prevalence of erosive esophagitis of >10%
and symptom-based studies show a prevalence of
6–10% [5]. As with other populations, a substantial
portion of Asian patients with GERD fail to respond to
PPI therapy. In one study, 20% of patients with erosive
reflux disease (ERD) and 33% of those with non-
erosive reflux disease (NERD) did not achieve adequate
response after receiving a PPI [9]. Here we report an
analysis of data from five countries – Hong Kong,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited.
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the predictors of symptomatic response to pantopra-
zole in Asian patients with GERD. This is the first
study of its kind performed in Asian patients.Methods
Study design
Asian patients were enrolled as part of a large multicen-
ter, multinational, prospective, open study conducted
from May 2006 to March 2007 (ClinicalTrial.gov identi-
fier: NCT00312806), the full trial design details of which
have been previously reported [4]. In brief, a pragmatic
study design was adopted to resemble conditions of ordin-
ary clinical practice as much as possible, thereby optimizing
the likelihood that the results would be relevant to everyday
practice [10,11]. The study was developed in accordance
with the Declaration of Helsinki and ethics approval was
obtained from the relevant local ethics committee: Joint
Chinese University of Hong Kong- New Territories East
Cluster Clinical Research Ethics Committee (Hong Kong);
Medical Research & Ethics Committee, Institute of Medical
Research (Malaysia); Medical Ethics Committee, University
Malaya Medical Center (Malaysia) Singapore General Hos-
pital Institutional Review Board (Singapore); Institutional
Review Board Asan Medical Center (South Korea); Institu-
tional Review Board, The Catholic University of Korea,
Kangnam St. Mary’s Hospital (South Korea); Institutional
Review Board, Seoul National University Hospital (South
Korea); Institutional Review Board, Yongdong Severance
Hospital (South Korea); Institutional Review Board,
Samsung Medical Center (South Korea); Human Ex-
periment and Ethics Committee, National Cheng Kung
University Hospital (Taiwan); Joint Institutional Review
Board (Taiwan); Institutional Review Board of Tri-Service
General Hospital, National Defense Medical Center
(Taiwan). All patients provided written informed con-
sent prior to enrolment.
Eligible patients were aged ≥18 years and had symp-
toms considered by the investigating physician to justify
a diagnosis of GERD, without further specification of
GERD diagnostic criteria. Patients were excluded from
the study if they had symptoms or evidence of complicated
GERD, previous upper gastrointestinal (GI) surgery or had
received Helicobacter pylori (H. pylori) eradication treat-
ment in the 4 weeks preceding the study. Those who had
recently taken acid-suppressing medications, corticoste-
roids, non-steroidal anti-inflammatory drugs (NSAIDs) or
prokinetics were also excluded. During the study, patients
were not permitted to use acid-suppressing medications,
corticosteroids, NSAIDs, prokinetics, sucralfate, misopros-
tol, bismuth preparations, substances that affect the relief of
acid-related symptoms, ketoconazole or drugs showing pH-
dependent absorption.After enrolment, upper GI endoscopy was performed.
Patients were categorized as having ERD or NERD, and
grade of esophagitis was assigned according to the Los
Angeles classification [12,13]. Patients with esophageal
stricture, a Schatzki’s ring, an esophageal diverticulum,
esophageal varices, or Barrett’s esophagus on endoscopy
were excluded. At this time, H. pylori status was deter-
mined by serology [14]. Participants received pantopra-
zole 40 mg to be taken once daily before breakfast over
the 8-week study period. Patients were required to at-
tend the investigation center on three occasions during
this period.
Assessments
ReQuest™ questionnaire
ReQuest™ is a self-administered questionnaire that as-
sesses seven dimensions of GERD (acid complaints,
upper abdominal/stomach complaints, lower abdominal/
digestive complaints, nausea, sleep disturbances, other
complaints, and general well-being) to provide a com-
prehensive evaluation of the intensity and frequency of
symptoms [15-17]. The dimensions of ReQuest™ can be
grouped into two sub-scales: ReQuest™-GI, which in-
cludes acid complaints, upper abdominal/stomach com-
plaints, lower abdominal/digestive complaints, and
nausea, and ReQuest™-WSO, which is comprised of gen-
eral well-being, sleep disorders, and other complaints.
Both a long and a short version of ReQuest™ have been
validated in several languages. The short version of Re-
Quest™ was used in this study, and was completed by
participants on Day 0 (i.e. the day before commencing
treatment) and then daily thereafter. Patients were deter-
mined to be treatment ‘responders’ if their ReQuest™-GI
symptom score was below 1.6 on three consecutive days.
A score of 1.6 was determined as the threshold symptom
score for ReQuest™-GI in an international study of 1167
healthy subjects who completed ReQuest™ on four con-
secutive days. The intensity and frequency of ReQuest™
dimensions were scored and weighted and the sum scores
of ReQuest™ and its subscales corresponding to the 95%
percentiles were calculated as threshold scores [18]. These
scores corresponded with those obtained for a German
population [19], indicating that the threshold concept was
reliable and valid for use in clinical trials [18,19].
HADS, GERDyzer™ and treatment satisfaction
The Hospital Anxiety Depression Scale (HADS) and
GERD Analyzer (GERDyzer™) questionnaires were com-
pleted on Day 0. These questionnaires, along with the
treatment satisfaction sheet, were then completed at
Week 4 and Week 8. The treatment satisfaction sheet
was used to categorize patient satisfaction with symptom
control during the 24 hours preceding the Week 4 and
Week 8 study visit as ‘very satisfied’, ‘fairly satisfied’ or
Table 1 Baseline and demographic characteristics
Gender, n (%)
Male 101 (48.3)
Female 108 (51.7)
Age, years, mean (SD) 48.5 (12.12)
Height, cm, mean (SD) 164.1 (7.97)
Weight, Kg, mean (SD) 64.9 (12.20)
BMI, mean (SD) 24.0 (3.50)
Cigarette smoking, n (%)
Never 150 (71.8)
Former 27 (12.9)
Current 32 (15.3)
Country of origin, n (%)
Hong Kong 26 (12.4)
South Korea 86 (41.1)
Malaysia 38 (18.2)
Singapore 7 (3.3)
Taiwan 52 (24.9)
Intent-to-treat population (N = 209).
BMI, Body mass index; SD, Standard deviation.
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measure for anxiety and depression used in outpatient
clinics. In this study, the HADS was used to assess rela-
tionships between the patients’ symptoms and psycho-
logical constitution, according to the standard scoring
method [20,21].
Finally, the GERDyzer™ is a questionnaire that evalu-
ates the impact of GERD on a patient’s quality of life
across 10 dimensions: general well-being, pain/discom-
fort, physical health, energy, daily activities, leisure activ-
ities, social life, diet/eating/drinking habits, mood and
sleep [22]. Each dimension is assessed using a 100 mm
visual analogue scale ranging from ‘not at all’ to ‘very
much’, with the exception of ‘general well-being’, which
is assessed from ‘excellent to ‘unbearably bad’. Higher
GERDyzer™ scores indicate greater impairment of quality
of life.
Statistical analysis
All efficacy data are presented for the intent-to-treat
(ITT) population (N = 209), which consists of all patients
who received at least one dose of the study medication.
Safety data are presented for 210 patients who were
recruited in the study. Age, body mass index (BMI), gen-
der, smoking status, H. pylori status, symptoms suggest-
ing irritable bowel syndrome, presence of esophagitis
before treatment, baseline ReQuest™-GI score, and the
HADS total and sub-scores were investigated as possible
influences on response to treatment at 8 weeks using ap-
plicable statistical tests (two-group t-tests for numerical
data and the chi-square test for categorical data). A p-
value of <0.1 was taken to indicate significant influence
of the independent variable. Following univariate ana-
lysis, a global multivariate logistic regression was per-
formed using the response to treatment of patients as
the dependent variable and those variables identified as
possibly having an influence on response as independent
variables, to take into account any effects of confound-
ing. Results were not analyzed at the individual country
level because of small sample sizes.
A possible association between GERDyzer™ score and
the HADS total score was examined for each visit using
Pearson’s correlation coefficient. Similarly, an association
between GERDyzer™ score and patient satisfaction, and
the HADS total score and patient satisfaction, was ex-
amined for each visit under treatment, and the post-
treatment patient satisfaction and baseline scores were
examined using Pearson’s correlation coefficient.
Results
In total, 210 participants were recruited in five Asian coun-
tries; this comprised the safety population. The ITT popula-
tion comprised 209 individuals. Baseline and demographic
characteristics are presented in Table 1.Response rates
The overall response rates (i.e., ReQuest™-GI symptom
score below 1.6 on 3 consecutive days) for the ITT
population were 44.3% at Week 4 and 63.6% at Week 8
(Figure 1). This was lower than those reported for the
rest of the world (16 countries: Europe, UK, North and
South America, Africa, India and Australia) (60.7 at
Week 4 [P < 0.001, chi square] and 72.2 at Week 8
[P = 0.010, chi square]). At the end of the 8 weeks of
treatment, patients who had ERD pre-treatment showed
higher response rates than those with NERD (71.3% vs.
48.5%). Response rates for patients with baseline ERD and
NERD in Asia follow a similar pattern to those seen in the
rest of the world (69.6% and 60.7%), although there tends
to be fewer responders in the NERD group.
In univariate analyses other variables studied, includ-
ing age, gender, cigarette smoking and H. pylori status,
had no significant effect on response to pantoprazole.
HADS scores were the exception, with lower mean base-
line HADS total scores (P = 0.0149) and lower mean
baseline depression subscale scores (P < 0.0128) occur-
ring in responders versus non-responders.
Multiple logistic regression analysis data assessing the
influence of various factors on response rates following
pantoprazole treatment are presented in Table 2. The
presence of ERD (P = 0.0143) and lower ReQuest™-GI
scores at baseline (P = 0.0222) were associated with a re-
sponse to therapy. BMI and HADS subscores had no
significant influence on response rates.
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Figure 1 Percentage of patients responding to pantoprazole
40 mg once daily at Week 4 and Week 8 of treatment. A
comparison of Asian populations (combined: Hong Kong, Korea,
Malaysia, Singapore and Taiwan) with the rest of the world.
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scores) at 4 and 8 weeks, was associated with response to
treatment, with responders in the Asian population scoring
lower on GERDyzer™ than non-responders at each time
point (Figure 2; P < 0.0001). Similar results were observed
for the rest of the world (Figure 2; P < 0.0001). In addition,
response to treatment was associated with improvement in
anxiety and depression, as indicated by a lower HADS total
score, at 4 and 8 weeks in both the Asian population and
the rest of the world (Figure 3; both P < 0.0001).
Control of symptoms and patient satisfaction
At 8 weeks following treatment, more patients who had
responded to treatment than had not responded reported
that they were satisfied with symptom control in the pre-
ceding 24 hours in both the Asia population (P < 0.0001)
and the rest of the world (P < 0.0001; Figure 4). Further-
more, greater satisfaction with treatment at Week 4 and
Week 8 was reported in those who had improvements in
anxiety and depression (assessed by total HADS score)
at these same time points (Week 4: P < 0.0001; Week 8:
P < 0.0001), irrespective of baseline HADS scores. Simi-
larly, improved quality of life (assessed by GERDyzer™)
was also associated with greater patient satisfaction atTable 2 Factors influencing treatment response
Factor Logistic regression P-value
ERD/NERD 0.0143
ReQuest™-GI at baseline 0.0222
BMI 0.0831
HADS
Anxiety subscale 0.7355
Depression subscale 0.2130
BMI, Body mass index; ERD, Erosive reflux disease; GI, Gastrointestinal; HADS,
Hospital Anxiety and Depression Scale; NERD, Non-erosive reflux disease.Week 4 (P < 0.0001) and Week 8 (P < 0.0001), irrespect-
ive of GERDyzer™ scores at baseline.
Safety
Over the course of the study, 74 adverse events (AEs)
were reported by 50 patients in the safety set (23.8%), a
similar rate to that reported for the rest of the world
(25.2% of 1718 patients). Most AEs were of mild inten-
sity (86.5%) and were considered unrelated to the study
medication by the investigator (77.0%). Only 5.4% of
AEs were considered to be likely related and none were
considered to be definitely related to the study medica-
tion. Two patients (1%) experienced treatment-emergent
serious adverse events (SAE) during the trial. Both SAE’s
were of severe intensity. One patient had myalgia, which
was assessed as unlikely related to the study medication
by the investigator. The sudden hearing loss of the other
patient was assessed to have no relation to the study
medication by the investigator. No patients died during
the study.
The most common treatment-emergent AEs were diar-
rhea (5.2%), upper respiratory tract infection (3.3%) and
nasopharyngitis (2.9%); other events occurred in <2% of the
population (Table 3). Treatment-emergent AEs in the Asian
population generally occurred at a similar frequency to
those in participants from the rest of the world, with the
exception of diarrhea, which was more commonly reported
in Asia (5.2% vs. 2.7%), and headache, which was more
commonly reported in the rest of the world (1.4% vs. 4.0%
for Asia vs. the rest of the world).
Discussion
This is the first international, multicenter outcome study
in patients with GERD in Asia. In the setting of everyday
clinical practice, response rates to pantoprazole treat-
ment at 8 weeks were 63.6% across five Asian popula-
tions, indicating that some patients fail to adequately
respond to PPI therapy. Two features, the presence of
erosive disease and less severe GI symptoms, seemed
predictive of response and these may be helpful in deter-
mining the likely success of pantoprazole treatment in
controlling symptoms in GERD in Asian patients, thereby
helping to manage patient expectations. More complete
symptom control, as assessed by ReQuest™-GI, was associ-
ated with greater patient satisfaction, better quality of life,
and greater improvements in anxiety and depression, at
Weeks 4 and 8.
This analysis was part of a larger study designed to ob-
tain information relevant to everyday clinical practice,
whereby patients with GERD often present with a symp-
tom burden that is more complex than heartburn alone
[23], many patients do not have esophagitis and treatment
with a PPI is undertaken without first obtaining an upper
GI endoscopy. It should be noted that pantoprazole 20 mg
0100
200
300
400
500
600
Non-responder
Responder
Rest of worldAsia 
G
ER
D
yz
er
™
 to
ta
l s
co
re
, m
ea
n 
(S
D
)
Day 1 Week 4 Week 8 Day 1 Week 4 Week 8
*
* * *
*P < 0.0001
Figure 2 Improvement in quality of life (total GERDyzerTM score) by patient response to treatment (assessed using ReQuestTM-GI).
A comparison of Asian populations (combined: Hong Kong, Korea, Malaysia, Singapore and Taiwan) with the rest of the world.
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ever, to replicate clinical practice where treatment is usually
started on the basis of clinical history rather than endos-
copy, a 40 mg dose of pantoprazole was chosen for all pa-
tients in this study. The higher dosage used in NERD
patients could have potentially increased response rates, al-
though the impact of this is likely to be small as previous
studies have shown similar symptom response rates with
pantoprazole 20 and 40 mg, even in patients with mild
GERD [25]. The study had a pragmatic trial design and pa-
tients were enrolled in the trial on the basis of a clinical his-
tory of GERD, which allowed for the collection of data0
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A comparison of Asian populations (combined: Hong Kong, Korea, Malaysiarelevant to daily clinical practice, unlike trials of explanatory
design, which may enroll a patient population that is not
representative of that being treated in ordinary practice
[10,11]. Explanatory trials often overestimate the success of
treatment compared with outcomes achieved in ordinary
clinical practice [26].
The current analysis provides a treatment response
rate of 63.6% (Week 8) across Asia, which is slightly
lower than those previously reported in the literature
[9]. PPI response rates were 80% in patients with ERD
and 67% in those with NERD in one study [9]. Of note,
these response rates are also lower than those reportedNon-responder
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Rest of world
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tient response to treatment (assessed using ReQuestTM-GI).
, Singapore and Taiwan) with the rest of the world.
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were also observed in Australia in the previously pub-
lished analysis, in which the influence of geography on
response rates was assessed. These overall results for the
Asian population may be driven by the lower response
rates in patients with NERD (48.5%) than in those with
ERD (71.3%), as these vary substantially from data for
the rest of the world (60.7%). This is consistent with
other studies that have shown that patients with NERD
tend to respond less well to PPI treatment than those
with ERD [1,27,28]. While Asian patients were included
in the international validation studies for both ReQuest™
and GERDyzer™, it has also been reported that theTable 3 Frequently reported treatment-emergent adverse
events
MedDRA preferred term Asia (N = 210),
n (%)
Rest of the world
(N = 1718), n (%)
Diarrhea 11 (5.2) 47 (2.7)
Upper respiratory tract infection 7 (3.3) 8 (0.5)
Nasopharyngitis 6 (2.9) 10 (0.6)
Headache 3 (1.4) 69 (4.0)
Vomiting 3 (1.4) 10 (0.6)
Constipation 2 (1.0) 18 (1.0)
Heart rate increased 2 (1.0) 0 (0.0)
Insomnia 2 (1.0) 13 (0.8)
Nausea 0 (0.0) 33 (1.9)
Abdominal pain 1 (0.5) 22 (1.3)
Influenza 0 (0.0) 19 (1.1)
A comparison of Asian populations with the rest of the world (intent-to-treat
population, N = 210).interpretation and reporting of reflux symptoms is sub-
ject to ethnic variation [29], with Asian populations
experiencing more atypical symptoms, such as chest
pain, and Western populations reporting more heart-
burn [5,6]. Of consideration, there is lack of appropriate
terminology in some Asian languages for heartburn [30]
and one study has shown that patients of East Asian ori-
gin did not understand the symptom of heartburn [29].
We cannot definitively rule out ethnic variation in symp-
tom reporting as a possible cause for the differences be-
tween Asian populations and the rest of the world.
Nonetheless the short version of ReQuest™ quantifies the
four dimensions that make up ReQuest™-GI each on an
individual 7-point Likert scale, without the mention to
specific symptoms, suggesting that patients assess these
scales based on their predominant symptoms [23]. In-
deed, ReQuest™ was designed to avoid an assessment of
symptom response based primarily on heartburn [23]. It
should be noted that this sample is only reflective of the
whole Asian population (as is the sample for the rest of
the world). Obtaining a truly representative sampling
across many countries is always difficult; nonetheless,
data across as broad a population as possible were care-
fully collected in this multicenter study. Further studies
on the ethnic differences in morbidity and treatment re-
sponse of GERD patients in Asia are needed.
Patients with less severe GI symptoms (lower scores
on ReQuest™-GI) showed a better response to pantopra-
zole treatment. Previous reports have shown that treat-
ment outcome may be predicted by symptom severity
before or shortly after commencing treatment [31-35].
Previously reported results for the total population
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dictive ability for outcomes at Week 8, although the au-
thors suggested that the predictive accuracy may be
lower than physicians would wish [4]. Nonetheless, the
scores obtained from the abbreviated form of ReQuest™
(ReQuest in Practice™ [36]) have been shown to be more
accurate than the physicians’ conventional clinical en-
quiry in identifying patients whose symptoms would
continue to be controlled after stepping down from full
dose to half dose PPI therapy [37], suggesting value in
the systematic assessment of symptom burden in clinical
practice.
It might be expected that patients with concurrent
anxiety or depression would respond poorly to GERD
treatment, as has been shown in previous studies
[32,38]. Although in the current study higher mean
baseline HADS total scores and depression subscale
scores predicted non-response to pantoprazole treat-
ment in univariate analyses, this was not borne out in
the multivariate analysis. However, improvement in
anxiety and depression with treatment was associated
with more complete symptoms control and greater pa-
tient satisfaction following 4–8 weeks’ treatment. This
potentially supports the notion that psychological dis-
tress, such as anxiety and depression, may be a conse-
quence of poorly controlled GERD symptoms, rather
than a contributing factor to severe reflux symptoms.
However, this study did not contain a placebo group;
therefore, there is the potential that response to these
subjective psychological measures may have been over
estimated. Interpretations of the data thus require
further substantiation.
Lower BMI has been associated with poorer treatment
response to PPI therapy in previous studies in Western
populations [39], and also in the total worldwide popula-
tion for the current study [4]. In this analysis of five
Asian populations, BMI fell just short of statistical sig-
nificance (P = 0.0831), which suggests that there might
be a possible effect of BMI on treatment outcome (beta
risk). Further research is required to confirm whether or
not BMI affects response to PPI therapy in Asian popula-
tions as it does in other groups. Along with BMI, female
gender, anxiety and IBS were also factors predicting re-
sponse in the total global population for this study [4] but
not in the Asian subgroup.
Conclusions
Asian patients with GERD, especially those with NERD,
appear to have lower response rates to PPI treatment
than Western populations. Some readily identifiable fea-
tures, such as the presence of erosive disease and less se-
vere GI symptoms, may help to predict symptomatic
responses to a PPI in Asian patients, which may help in
managing patient expectations.Competing interests
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